Hemodynamics, fluids & transfusion
Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial
Primary result · RBC transfusionResult — go to the resultRelative risk 0.99 95% CI 0.83–1.18Authors' conclusion
Results of this randomized clinical trial reveal that TXA did not reduce blood transfusion in patients undergoing open radical cystectomy for bladder cancer.
Study context
- Population
- Patients with planned open radical cystectomy for bladder cancer, 10 academic centers344 in ITT analysis
- Participants
- 353 patients
- Comparison
- Tranexamic acid (TXA) vs placebo during open radical cystectomy
- TXAn = 173
- Placebon = 171reference
- Primary endpoint
- Receipt of RBC transfusion
- Follow-up
- Up to 30 days after surgery
Methodological detailsdouble-blind, placebo-controlled, multicentre, Enrollment June 2013 to January 2021
- Double-blind
- Placebo-controlled
- Multicentre
- Enrollment June 2013 to January 2021
Primary result
RBC transfusion · up to 30 days
Relative risk
0.99
95% CI 0.83–1.18
Events by treatment group
TXA vs Placebo
RR 0.99 (95% CI 0.83–1.18)
As reported in the abstract
Secondary outcomes
Number of RBC units transfused
P = 0.43
Estimated blood loss
P = 0.52
Intraoperative transfusion
P = 0.08
Safety
Venous thromboembolic events
P = 0.57
Non-transfusion-related adverse events
- Similar between groups
Original publication
Tranexamic Acid During Radical Cystectomy: A Randomized Clinical Trial. JAMA Surg. Published 1 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →